GW Pharmaceuticals Inc. (fka GWPRF)

[jupp]

07:01 EDT GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock.

-----

10:38 EDT GW Pharmaceuticals soars after analyst nearly triples price target
Shares of Britain's GW Pharmaceuticals (GWPH) are jumping after a Lazard Capital analyst wrote that the company has one of the most compelling opportunities he's ever seen, and nearly tripled his price target on the stock. WHAT'S NEW: GW's CBD, a drug derived from the cannabis plant, has significantly helped some epilepsy patients to whom it has been administered, Lazard Capital analyst Joshua Schimmer wrote in a note to investors earlier today. Although not all the refractory childhood seizure patients who have taken the drug have improved, evidence suggests that the treatment does have "an antiseizure effect," the analyst believes after speaking with multiple experts. Moreover, "there is an enormous unmet need" for such an antiseizure treatment, and specialists appear to be extremely interested in CBD, Schimmer contended. He hiked his price target on GW to $65 from $22, and kept a Buy rating on the shares. TODAY'S PRICE ACTION: In mid-morning trading, GW rallied $5.95, or 24%, to $30.65.

www.theflyonthewall.com/permalinks/entry.php/GWPHid1896862/GWPH-GW-Pharmaceuticals-soars-after-analyst-nearly-triples-price-target